Key growth drivers included heart failure drug Entresto (sacubitril/valsartan), which will nevertheless face loss of exclusivity in the US this year
Manchanda said Canada and Brazil are the most attractive markets in the near term as key GLP-1 drugs approach patent expiry over the next year
is supported by MRC Clinician Scientist Fellowship MR/Y00132X/1, and by project grants from the MRC and Diabetes UK
Background and aims: Islets are central to glucose homeostasis and diabetes, but they were mainly investigated with square pulses of supraphysiological glucose
FDA Wilding JPH, Batterham RL, Calanna S, et al
Retatrutide from reputable Canadian suppliers typically costs $150-250 monthly at maintenance doses, representing significant savings compared to retail pharmacy pricing for approved medications